Theratechnologies Inc. - Asset Resilience Ratio
Theratechnologies Inc. (TH) has an Asset Resilience Ratio of 1.80% as of May 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Theratechnologies Inc. (TH) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Theratechnologies Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Theratechnologies Inc..
Liquid Assets Composition Over Time
This chart breaks down Theratechnologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Theratechnologies Inc. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$462.00K | 0.9% |
| Short-term Investments | CA$462.00K | 0.9% |
| Total Liquid Assets | CA$924.00K | 1.80% |
Asset Resilience Insights
- Limited Liquidity: Theratechnologies Inc. maintains only 1.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Theratechnologies Inc. Industry Peers by Asset Resilience Ratio
Compare Theratechnologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Theratechnologies Inc. (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Theratechnologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-11-30 | 13.96% | CA$7.45 Million ≈ $5.39 Million |
CA$53.34 Million ≈ $38.59 Million |
-2.22pp |
| 2023-11-30 | 16.18% | CA$12.58 Million ≈ $9.10 Million |
CA$77.77 Million ≈ $56.26 Million |
-3.58pp |
| 2022-11-30 | 19.76% | CA$18.43 Million ≈ $13.33 Million |
CA$93.26 Million ≈ $67.46 Million |
-13.72pp |
| 2021-11-30 | 33.48% | CA$39.91 Million ≈ $28.87 Million |
CA$119.21 Million ≈ $86.24 Million |
+17.44pp |
| 2020-11-30 | 16.04% | CA$16.06 Million ≈ $11.62 Million |
CA$100.14 Million ≈ $72.44 Million |
-4.32pp |
| 2019-11-30 | 20.35% | CA$23.93 Million ≈ $17.31 Million |
CA$117.56 Million ≈ $85.04 Million |
+2.92pp |
| 2018-11-30 | 17.43% | CA$19.39 Million ≈ $14.03 Million |
CA$111.25 Million ≈ $80.48 Million |
-38.28pp |
| 2017-11-30 | 55.71% | CA$33.03 Million ≈ $23.89 Million |
CA$59.29 Million ≈ $42.89 Million |
+43.17pp |
| 2016-11-30 | 12.54% | CA$4.95 Million ≈ $3.58 Million |
CA$39.43 Million ≈ $28.52 Million |
+4.93pp |
| 2014-11-30 | 7.61% | CA$2.17 Million ≈ $1.57 Million |
CA$28.51 Million ≈ $20.62 Million |
+7.21pp |
| 2013-11-30 | 0.40% | CA$93.25K ≈ $67.45K |
CA$23.40 Million ≈ $16.93 Million |
-0.01pp |
| 2012-11-30 | 0.41% | CA$150.00K ≈ $108.51K |
CA$36.58 Million ≈ $26.46 Million |
-1.01pp |
| 2011-11-30 | 1.42% | CA$728.26K ≈ $526.81K |
CA$51.20 Million ≈ $37.04 Million |
-1.17pp |
| 2010-11-30 | 2.60% | CA$1.82 Million ≈ $1.32 Million |
CA$70.28 Million ≈ $50.84 Million |
-11.85pp |
| 2009-11-30 | 14.44% | CA$9.49 Million ≈ $6.86 Million |
CA$65.70 Million ≈ $47.52 Million |
-5.79pp |
| 2008-11-30 | 20.23% | CA$8.82 Million ≈ $6.38 Million |
CA$43.60 Million ≈ $31.54 Million |
-16.59pp |
| 2007-11-30 | 36.82% | CA$27.45 Million ≈ $19.86 Million |
CA$74.55 Million ≈ $53.93 Million |
+1.46pp |
| 2006-11-30 | 35.36% | CA$15.79 Million ≈ $11.42 Million |
CA$44.65 Million ≈ $32.30 Million |
+12.03pp |
| 2005-11-30 | 23.33% | CA$10.72 Million ≈ $7.75 Million |
CA$45.93 Million ≈ $33.23 Million |
-2.44pp |
| 2004-11-30 | 25.77% | CA$14.75 Million ≈ $10.67 Million |
CA$57.23 Million ≈ $41.40 Million |
-15.78pp |
| 2003-11-30 | 41.55% | CA$30.28 Million ≈ $21.90 Million |
CA$72.88 Million ≈ $52.72 Million |
+13.72pp |
| 2002-11-30 | 27.83% | CA$24.98 Million ≈ $18.07 Million |
CA$89.78 Million ≈ $64.95 Million |
-6.75pp |
| 2001-11-30 | 34.58% | CA$31.25 Million ≈ $22.61 Million |
CA$90.38 Million ≈ $65.38 Million |
+2.10pp |
| 2000-11-30 | 32.48% | CA$17.86 Million ≈ $12.92 Million |
CA$54.99 Million ≈ $39.78 Million |
-48.33pp |
| 1999-11-30 | 80.81% | CA$14.87 Million ≈ $10.76 Million |
CA$18.40 Million ≈ $13.31 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more